The report assesses Inclusion Body Myositis
(IBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis
Unlike most connective tissue diseases, inclusion body myositis occurs predominantly in men.
The results will be abnormal in both conditions, but MRIs from patients with inclusion body myositis are more likely to show fatty infiltration and atrophy and more widespread abnormalities, while in polymyositis, the predominant abnormality seen on MRI is inflammation distributed along the fascia.
Sporadic inclusion body myositis and hereditary inclusion body myositis.
Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis.
A snapshot of the global therapeutic scenario for Inclusion Body Myositis (IBM).
Coverage of the Inclusion Body Myositis (IBM) pipeline on the basis of route of administration and molecule type.
Summary of Bcl-2, Bcl-X, and Bax Immunoreactivity in Inclusion Body Myositis (N = 27) Degene- Regene- Subsar- rating rating Autophagic colemmal Antibody Inflammation Fibers Fibers Vacuoles Staining Bax 26 (96) * 24 (89) 24 (89) 24 (89) 21 (78) Bcl-2 27 (100) 2 (7) 21 (78) 2 (7) 6 (22) Bcl-x 8 (30) 3 (11) 4 (15) 3 (11) 1 (4) * Values are expressed as number positive (%).
Mitochondrial deletions in inclusion body myositis.